Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Mar;35(3):490–496. doi: 10.1128/aac.35.3.490

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

T Iwahi 1, H Satoh 1, M Nakao 1, T Iwasaki 1, T Yamazaki 1, K Kubo 1, T Tamura 1, A Imada 1
PMCID: PMC245037  PMID: 2039199

Abstract

The activities of various types of antiulcer agents against Helicobacter pylori (formerly called Campylobacter pylori) strains were determined by an agar dilution method. Among the compounds tested, two benzimidazole proton pump inhibitors, lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole. A major metabolite and two acid-converted rearrangement products of lansoprazole also exhibited good activities comparable or superior to that of the parent compound. Exposure to lansoprazole of H. pylori growing in a liquid medium led to an extensive loss of viability without a reduction in culture turbidity and produced an aberrant bacterial morphology characterized by the irregular constriction of cells and the collapse of cell surface structures. The antibacterial activity of lansoprazole and its related compounds was selective against H. pylori; common aerobic and anaerobic bacteria and Campylobacter jejuni were not inhibited by 100 micrograms/ml.

Full text

PDF
490

Images in this article

494Image
on p.494
494Image
on p.494

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong J. A., Wee S. H., Goodwin C. S., Wilson D. H. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study. J Med Microbiol. 1987 Dec;24(4):343–350. doi: 10.1099/00222615-24-4-343. [DOI] [PubMed] [Google Scholar]
  2. Biasco G., Miglioli M., Barbara L., Corinaldesi R., di Febo G. Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer. Lancet. 1989 Dec 9;2(8676):1403–1403. doi: 10.1016/s0140-6736(89)92021-7. [DOI] [PubMed] [Google Scholar]
  3. Blaser M. J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990 Apr;161(4):626–633. doi: 10.1093/infdis/161.4.626. [DOI] [PubMed] [Google Scholar]
  4. Eberhardt R., Kasper G. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer. Rev Infect Dis. 1990 Jan-Feb;12 (Suppl 1):S115–S119. doi: 10.1093/clinids/12.supplement_1.s115. [DOI] [PubMed] [Google Scholar]
  5. García-Rodríguez J. A., García Sánchez J. E., García García M. I., García Sánchez E., Muñoz Bellido J. L. In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori. Antimicrob Agents Chemother. 1989 Sep;33(9):1650–1651. doi: 10.1128/aac.33.9.1650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Glupczynski Y., Labbe M., Burette A., Delmee M., Avesani V., Bruck C. Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet. 1987 May 9;1(8541):1096–1096. doi: 10.1016/s0140-6736(87)90527-7. [DOI] [PubMed] [Google Scholar]
  7. Goodwin C. S., Armstrong J. A. Microbiological aspects of Helicobacter pylori (Campylobacter pylori). Eur J Clin Microbiol Infect Dis. 1990 Jan;9(1):1–13. doi: 10.1007/BF01969526. [DOI] [PubMed] [Google Scholar]
  8. Goodwin C. S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986 Mar;17(3):309–314. doi: 10.1093/jac/17.3.309. [DOI] [PubMed] [Google Scholar]
  9. Graham D. Y. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):615–625. doi: 10.1016/s0016-5085(89)80057-5. [DOI] [PubMed] [Google Scholar]
  10. Hardy D. J., Hanson C. W., Hensey D. M., Beyer J. M., Fernandes P. B. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother. 1988 Nov;22(5):631–636. doi: 10.1093/jac/22.5.631. [DOI] [PubMed] [Google Scholar]
  11. Hazell S. L., Lee A., Brady L., Hennessy W. Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis. 1986 Apr;153(4):658–663. doi: 10.1093/infdis/153.4.658. [DOI] [PubMed] [Google Scholar]
  12. Humphreys H., Bourke S., Dooley C., McKenna D., Power B., Keane C. T., Sweeney E. C., O'Moráin C. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut. 1988 Mar;29(3):279–283. doi: 10.1136/gut.29.3.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lambert T., Mégraud F., Gerbaud G., Courvalin P. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother. 1986 Sep;30(3):510–511. doi: 10.1128/aac.30.3.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mainguet P., Delmée M., Debongnie J. C. Omeprazole, campylobacter pylori, and duodenal ulcer. Lancet. 1989 Aug 12;2(8659):389–390. doi: 10.1016/s0140-6736(89)90569-2. [DOI] [PubMed] [Google Scholar]
  15. Marshall B. J., Armstrong J. A., Francis G. J., Nokes N. T., Wee S. H. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion. 1987;37 (Suppl 2):16–30. doi: 10.1159/000199555. [DOI] [PubMed] [Google Scholar]
  16. Marshall B. J., Armstrong J. A., McGechie D. B., Glancy R. J. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 1985 Apr 15;142(8):436–439. doi: 10.5694/j.1326-5377.1985.tb113443.x. [DOI] [PubMed] [Google Scholar]
  17. Marshall B. J., Warren J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984 Jun 16;1(8390):1311–1315. doi: 10.1016/s0140-6736(84)91816-6. [DOI] [PubMed] [Google Scholar]
  18. McNulty C. A., Dent J. C., Ford G. A., Wilkinson S. P. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother. 1988 Nov;22(5):729–738. doi: 10.1093/jac/22.5.729. [DOI] [PubMed] [Google Scholar]
  19. McNulty C. A., Dent J., Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother. 1985 Dec;28(6):837–838. doi: 10.1128/aac.28.6.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McNulty C. A., Gearty J. C., Crump B., Davis M., Donovan I. A., Melikian V., Lister D. M., Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986 Sep 13;293(6548):645–649. doi: 10.1136/bmj.293.6548.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mertens J. C., Dekker W., Ligtvoet E. E., Blok P. Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia. Antimicrob Agents Chemother. 1989 Feb;33(2):256–257. doi: 10.1128/aac.33.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Morgan D. R., Freedman R., Depew C. E., Kraft W. G. Growth of Campylobacter pylori in liquid media. J Clin Microbiol. 1987 Nov;25(11):2123–2125. doi: 10.1128/jcm.25.11.2123-2125.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Morris A., Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol. 1987 Mar;82(3):192–199. [PubMed] [Google Scholar]
  24. Nagaya H., Satoh H., Kubo K., Maki Y. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther. 1989 Feb;248(2):799–805. [PubMed] [Google Scholar]
  25. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  26. Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  27. Satoh H., Inatomi N., Nagaya H., Inada I., Nohara A., Nakamura N., Maki Y. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther. 1989 Feb;248(2):806–815. [PubMed] [Google Scholar]
  28. Shungu D. L., Nalin D. R., Gilman R. H., Gadebusch H. H., Cerami A. T., Gill C., Weissberger B. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents. Antimicrob Agents Chemother. 1987 Jun;31(6):949–950. doi: 10.1128/aac.31.6.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Simor A. E., Ferro S., Low D. E. Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori. Antimicrob Agents Chemother. 1989 Jan;33(1):108–109. doi: 10.1128/aac.33.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Stone J. W., Wise R., Donovan I. A., Gearty J. Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach. J Antimicrob Chemother. 1988 Jul;22(1):92–93. doi: 10.1093/jac/22.1.92. [DOI] [PubMed] [Google Scholar]
  31. Unge P., Gnarpe H. Pharmacokinetic, bacteriological and clinical aspects on the use of doxycycline in patients with active duodenal ulcer associated with Campylobacter pylori. Scand J Infect Dis Suppl. 1988;53:70–73. [PubMed] [Google Scholar]
  32. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983 Jun 4;1(8336):1273–1275. [PubMed] [Google Scholar]
  33. Van Caekenberghe D. L., Breyssens J. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother. 1987 Sep;31(9):1429–1430. doi: 10.1128/aac.31.9.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wyatt J. I., Dixon M. F. Chronic gastritis--a pathogenetic approach. J Pathol. 1988 Feb;154(2):113–124. doi: 10.1002/path.1711540203. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES